Your Source for Venture Capital and Private Equity Financings

Shennon Biotechnologies Inks $13M Seed Round

2023-03-13
SAN FRANCISCO, CA, Shennon Biotechnologies the close of a $13M oversubscribed seed financing round led by DCVC.
Shennon Biotechnologies (ShennonBio), a biotech company using a proprietary single cell platform to create more effective immunotherapies, announced the close of a $13M oversubscribed seed financing round led by DCVC, with participation from Foundation Capital, AV8 and angel investors.

Founded in 2021, ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level within a few hours, enabling the identification of TCR or antibody targets to develop more precise and effective immunotherapies.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors